DSS - Investor FAQs

What is the primary business of DSS today?

DSS, Inc. is a multinational company engaged in various business segments including product packaging, biotechnology, consumer goods, commercial lending, securities and investment management. The company operates on a unique distribution sharing system where shareholders receive stakes in its subsidiaries through IPO spin-offs, strategically unlocking value.

DSS has established a solid foundation for sustainable growth through the acquisition and formation of a diversified portfolio of companies. These entities operate in five high-growth sectors, offering innovative solutions that meet customer needs and drive sustainable value creation.

As of now, DSS operates several distinct business lines globally: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management. Each business line is at different stages of development and income generation, contributing to DSS's overall strategic objectives.

How many shares are outstanding, and in float?

7,066,772 shares are issued and outstanding (as of 6/1/2024)

2,877,958 shares in the public float (as of 6/1/2024)

What is the status of the Impact Biomedical Initial Public Offering?

The IPO Offering is expected to be completed by late July, subject to SEC and FINRA approvals and contingent on market conditions.

When will the previously distributed Impact Biomedical stock dividend to DSS shareholders be freely traded?

The Impact Biomedical stock dividend will be deemed freely trading six months from the Impact Biomedical IPO.

What products are closest to commercialization in the Impact Biomedical pipeline?

Impact Biomedical has a broad portfolio of technologies and products that range from development to commercial stage. Examples of products closer to commercialization include probiotics and air purification. In addition, the company has licensed its Linebacker and Equivir technology, which is being developed by its licensed partner, ProPhase Labs (Nasdaq:PRPH). For more information Impact Biomedical’s pipelines can be viewed here: https://www.impactbiomedinc.com/pipeline/

Which business segments currently contribute the most to DSS's revenue numbers?

Currently, Product Packaging & Securities generate the most revenue for the company.

List revenue producing segments and their revenue numbers:

*Year Ended December 31, 2023
Product Packaging $18,497,000
Direct Marketing $6,088,000
Securities $5,288,000
Commercial Banking $385,000
Total Revenue $30,258,000

List revenue producing segments and their revenue numbers including expected growth (ie. AMRE etc.)

Product Packaging: $11,876,000
Commercial Lending: $644,000
Consumer: $18,000,000
Biotechnology: $94,000
Securities: $4,817,000
Corporate: $496,000